Financial overview

Herantis Pharma financial report data and keyfigures. History for income statement, balance sheet and cash flow.

Pre
Pre
Pre

Description

Herantis Pharma is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. The company's lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. Herantis Pharma was founded in 2008 and has its headquarters in Espoo, Finland.

Biotechnology